Equities Analysts Offer Predictions for BRNS FY2025 Earnings

Barinthus Biotherapeutics plc (NASDAQ:BRNS) – Research analysts at William Blair lowered their FY2025 earnings per share estimates for shares of Barinthus Biotherapeutics in a note issued to investors on Wednesday, May 7th. William Blair analyst A. Hsieh now expects that the company will earn ($1.63) per share for the year, down from their previous estimate of ($1.52). The consensus estimate for Barinthus Biotherapeutics’ current full-year earnings is ($1.38) per share. William Blair also issued estimates for Barinthus Biotherapeutics’ FY2026 earnings at ($1.69) EPS.

A number of other research firms have also recently commented on BRNS. HC Wainwright reiterated a “buy” rating and issued a $3.00 price target on shares of Barinthus Biotherapeutics in a research note on Friday, March 21st. Alliance Global Partners reissued a “buy” rating on shares of Barinthus Biotherapeutics in a report on Monday, March 24th.

Barinthus Biotherapeutics Stock Down 2.2%

Shares of Barinthus Biotherapeutics stock opened at $0.91 on Monday. The company has a market cap of $36.70 million, a P/E ratio of -0.61 and a beta of -0.80. Barinthus Biotherapeutics has a 52-week low of $0.64 and a 52-week high of $2.44. The firm’s 50 day moving average price is $0.88 and its 200-day moving average price is $1.01.

Barinthus Biotherapeutics (NASDAQ:BRNS) last issued its quarterly earnings data on Wednesday, May 7th. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.15).

Institutional Trading of Barinthus Biotherapeutics

A hedge fund recently bought a new stake in Barinthus Biotherapeutics stock. HighTower Advisors LLC acquired a new position in shares of Barinthus Biotherapeutics plc (NASDAQ:BRNS) during the first quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 37,450 shares of the company’s stock, valued at approximately $36,000. HighTower Advisors LLC owned 0.09% of Barinthus Biotherapeutics at the end of the most recent reporting period. 25.20% of the stock is currently owned by institutional investors.

Barinthus Biotherapeutics Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.